Esperion has reached a settlement with Renata Limited, agreeing not to market a generic version of NEXLETOL or NEXLIZET until April 19, 2040, resolving patent litigation.
Why it matters. This settlement affects Esperion's patent protection and market exclusivity for NEXLETOL and NEXLIZET, impacting their revenue and competitive position.
Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate).
This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to…
The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a…
